{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087269","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.740022+00:00","generated_at":"2026-06-12T07:36:09.454667+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagonist Q2 net loss $38.5M; JNJ-2113 advances to Phase 3 in psoriasis","bullets":["Net loss of $38.5M ($0.68/share) in Q2 2023 vs $41M loss in Q2 2022; cash $313.4M at June 30.","JNJ-2113 Phase 2b FRONTIER 1 met all endpoints; 78.6% PASI 75 at 100mg BID; moving to Phase 3 psoriasis and Phase 2b UC.","Rusfertide Phase 2 REVIVE positive results presented at EHA2023; Phase 3 VERIFY enrollment continues targeting Q1 2024 completion.","Completed $115M equity financing in April 2023.","License revenue $0 vs $0.9M in Q2 2022 as prior period included $25M milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087269","json":"https://secwatch.observer/filing/0001104659-23-087269.json","markdown":"https://secwatch.observer/filing/0001104659-23-087269.md","text":"https://secwatch.observer/filing/0001104659-23-087269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/0001104659-23-087269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/tm2322752d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:36:09.454667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf86fa2c734adcc732c98c515f3355189a6d7c58","claim":"Protagonist Therapeutics, Inc reported the second quarter ended June 30, 2023 results: revenue zero, net income Net loss was $38.5 million, or $0.68 per share, for the three months ended June 30, 2023, EPS $0.68 per share.","evidence_excerpt":"On August 3, 2023, Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/0001104659-23-087269-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"zero"},{"label":"Net income","value":"Net loss was $38.5 million, or $0.68 per share, for the three months ended June 30, 2023"},{"label":"EPS","value":"$0.68 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}